Your browser doesn't support javascript.
loading
Overview of AKR1C3: Inhibitor Achievements and Disease Insights.
Liu, Yang; He, Siyu; Chen, Ying; Liu, Yijun; Feng, Feng; Liu, Wenyuan; Guo, Qinglong; Zhao, Li; Sun, Haopeng.
Afiliação
  • Liu Y; School of Pharmacy, China Pharmaceutical University, Nanjing 211198, People's Republic of China.
  • He S; State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 210009, People's Republic of China.
  • Chen Y; Department of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing 211198, People's Republic of China.
  • Liu Y; School of Pharmacy, China Pharmaceutical University, Nanjing 211198, People's Republic of China.
  • Feng F; Jiangsu Food and Pharmaceuticals Science College, Institute of Food and Pharmaceuticals Research, Huaian 223005, People's Republic of China.
  • Liu W; Department of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing 211198, People's Republic of China.
  • Guo Q; School of Pharmacy, China Pharmaceutical University, Nanjing 211198, People's Republic of China.
  • Zhao L; State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 210009, People's Republic of China.
  • Sun H; State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 210009, People's Republic of China.
J Med Chem ; 63(20): 11305-11329, 2020 10 22.
Article em En | MEDLINE | ID: mdl-32463235

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Membro C3 da Família 1 de alfa-Ceto Redutase / Desenvolvimento de Medicamentos / Neoplasias / Antineoplásicos Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Membro C3 da Família 1 de alfa-Ceto Redutase / Desenvolvimento de Medicamentos / Neoplasias / Antineoplásicos Idioma: En Ano de publicação: 2020 Tipo de documento: Article